Search

Your search keyword '"de Groot, M. C. H."' showing total 33 results
Start Over Author "de Groot, M. C. H."
33 results on '"de Groot, M. C. H."'

4. Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications

Author

Abbing-Karahagopian, V., Huerta, C., Souverein, P. C., de Abajo, F., Leufkens, H. G. M., Slattery, J., Alvarez, Y., Miret, M., Gil, M., Oliva, B., Hesse, U., Requena, G., de Vries, F., Rottenkolber, M., Schmiedl, S., Reynolds, R., Schlienger, R. G., de Groot, M. C. H., Klungel, O. H., van Staa, T. P., van Dijk, L., Egberts, A. C. G., Gardarsdottir, H., and De Bruin, M. L.

Published
2014
Full Text
View/download PDF

5. Incidence Rates and Trends of Hip/Femur Fractures in Five European Countries: Comparison Using E-Healthcare Records Databases

Author

Requena, G., Abbing-Karahagopian, V., Huerta, C., De Bruin, M. L., Alvarez, Y., Miret, M., Hesse, U., Gardarsdottir, H., Souverein, P. C., Slattery, J., Schneider, C., Rottenkolber, M., Schmiedl, S., Gil, M., De Groot, M. C. H., Bate, A., Ruigómez, A., García Rodríguez, L. A., Johansson, S., de Vries, F., Montero, D., Schlienger, R., Reynolds, R., Klungel, O. H., and de Abajo, F. J.

Published
2014
Full Text
View/download PDF

9. Poster Presentations

Author

van Geffen, E. C. G., van der Wal, S. W., van Hulten, R., de Groot, M. C. H., Egberts, A. C. G., and Heerdink, E. R.

Published
2007
Full Text
View/download PDF

12. Seasonal changes in prescribing of long-acting beta-2-agonists-containing drugs

Author

Rottenkolber, M, Voogd, E, van Dijk, L, Primatesta, P, Becker, C, de Groot, M C H, Plana, E, Alvarez, Y, Durand, J, Slattery, J, Afonso, A, Requena, G, Huerta, C, Alvarez, A, de Abajo, F, Tauscher, M, Hasford, J, Fischer, R, Reynolds, R, Schmiedl, S, Sub Pharmacotherapy, Theoretical, Pharmacoepidemiology and Clinical Pharmacology, Sub Pharmacotherapy, Theoretical, and Pharmacoepidemiology and Clinical Pharmacology

Subjects
Pulmonary and Respiratory Medicine, Adult, Male, Pediatrics, medicine.medical_specialty, Adolescent, Long-acting beta-2 agonists, Prevalence, Seasonal variations, Drug Prescriptions, Severity of Illness Index, Young Adult, Administration, Inhalation, Medicine, Humans, COPD, Medical prescription, Practice Patterns, Physicians', Child, Adrenergic beta-2 Receptor Agonists, Asthma, Retrospective Studies, business.industry, Overlap syndrome, Secondary data, Seasonality, medicine.disease, Secondary data analysis, respiratory tract diseases, Europe, Long acting beta, Delayed-Action Preparations, Female, Seasons, business, Demography
Abstract

BACKGROUND: For patients with asthma, COPD, or asthma-COPD overlap syndrome (ACOS), inter-country comparisons of seasonal changes in drug prescriptions are scarce or missing. Hence, we aimed to compare seasonal changes in prescription rates of long-acting beta-2-agonist (LABA) in four European countries. METHODS: A common study protocol was applied to six health care databases (Germany, Spain, the Netherlands (2), and the UK (2)) to calculate age- and sex-standardized point prevalence rates (PPRs) of LABA-containing prescriptions by the 1st of March, June, September, and December of each year during the study period 2002-2009. Seasonal variation of PPRs was quantified using seasonal indexes (SIs; based on the ratio-to-moving-average-method) and SIs averaged over the study period (aSI) stratified by sex, age, and indication (asthma, COPD, or ACOS). RESULTS: There was a moderate seasonal change in LABA-containing prescriptions which was more pronounced in asthma or COPD patients compared to ACOS patients. For asthma and ACOS patients, highest seasonal variation was found for patients living in Spain (aSI: 87.3-110.7, aSI: 93.2-103.1) whereas for COPD highest seasonal variation was revealed for the NPCRD database (the Netherlands) (aSI: 92.2-105.6). Regarding age and sex, highest seasonal variation was found in Spanish boys under 10 years of age having a diagnosis of asthma. CONCLUSIONS: By applying a common analysis in six databases, we could observe moderate overall seasonal changes in LABA-containing prescription rates in patients with asthma, COPD, or ACOS.

Published
2015

13. A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction

Author

CDL Upod, Global Health, Circulatory Health, JC onderzoeksprogramma Methodologie, Afonso, A., Schmiedl, S., Becker, C., Tcherny-Lessenot, S., Primatesta, P., Plana, E., Souverein, P., Wang, Y., Korevaar, J. C., Hasford, J., Reynolds, R., de Groot, M. C H, Schlienger, R., Klungel, O., Rottenkolber, M., CDL Upod, Global Health, Circulatory Health, JC onderzoeksprogramma Methodologie, Afonso, A., Schmiedl, S., Becker, C., Tcherny-Lessenot, S., Primatesta, P., Plana, E., Souverein, P., Wang, Y., Korevaar, J. C., Hasford, J., Reynolds, R., de Groot, M. C H, Schlienger, R., Klungel, O., and Rottenkolber, M.

Published
2016

14. Association of polymorphisms in the beta-2 adrenergic receptor gene with fracture risk and bone mineral density

Author

Veldhuis-Vlug, A G, Oei, L, Souverein, P C, Tanck, M W T, Rivadeneira, F, Zillikens, M C, Kamphuisen, P W, Maitland-van der Zee, A H, de Groot, M C H, Hofman, A, Uitterlinden, A G, Fliers, E, de Boer, A, Bisschop, P H, Veldhuis-Vlug, A G, Oei, L, Souverein, P C, Tanck, M W T, Rivadeneira, F, Zillikens, M C, Kamphuisen, P W, Maitland-van der Zee, A H, de Groot, M C H, Hofman, A, Uitterlinden, A G, Fliers, E, de Boer, A, and Bisschop, P H

Abstract

Signaling through the beta-2 adrenergic receptor (B2AR) on the osteoblast influences bone remodeling in rodents. In the B2AR gene, three polymorphisms influence receptor function. We show that these polymorphisms are not associated with fracture risk or bone mineral density in the UCP, Rotterdam Study, and GEFOS cohorts.INTRODUCTION: Signaling through the beta-2 adrenergic receptor (B2AR) on the osteoblast influences bone remodeling in rodents. In the B2AR gene, three polymorphisms are known to influence receptor function in vitro and in vivo (rs1042713, rs1042714, and rs1800888). We examined the role of these polymorphisms in the B2AR gene on human bone metabolism.METHODS: We performed nested case-control studies to determine the association of these polymorphisms with fracture risk in the Utrecht Cardiovascular Pharmacogenetics (UCP) cohort and in three cohorts of the Rotterdam Study. We also determined the association of these polymorphisms with bone mineral density (BMD) in the GEFOS Consortium. UCP contains drug-dispensing histories from community pharmacies linked to national registrations of hospital discharges in the Netherlands. The Rotterdam Study is a prospective cohort study investigating demographics and risk factors of chronic diseases. GEFOS is a large international collaboration studying the genetics of osteoporosis. Fractures were defined by ICD-9 codes 800-829 in the UCP cohort (158 cases and 2617 unmatched controls) and by regular X-ray examinations, general practitioner, and hospital records in the Rotterdam Study (2209 cases and 8559 unmatched controls). BMD was measured at the femoral neck and lumbar spine using dual-energy X-ray absorptiometry in GEFOS (N = 32,961).RESULTS: Meta-analysis of the two nested case-control studies showed pooled odds ratios of 0.98 (0.91-1.05, p = 0.52), 1.04 (0.97-1.12, p = 0.28), and 1.16 (0.83-1.62, p = 0.38) for the associations between rs1042713, rs1042714, and rs1800888 per minor allele

Published
2015

15. Seasonal changes in prescribing of long-acting beta-2-agonists-containing drugs

Author

Sub Pharmacotherapy, Theoretical, Pharmacoepidemiology and Clinical Pharmacology, Rottenkolber, M, Voogd, E, van Dijk, L, Primatesta, P, Becker, C, de Groot, M C H, Plana, E, Alvarez, Y, Durand, J, Slattery, J, Afonso, A, Requena, G, Huerta, C, Alvarez, A, de Abajo, F, Tauscher, M, Hasford, J, Fischer, R, Reynolds, R, Schmiedl, S, Sub Pharmacotherapy, Theoretical, Pharmacoepidemiology and Clinical Pharmacology, Rottenkolber, M, Voogd, E, van Dijk, L, Primatesta, P, Becker, C, de Groot, M C H, Plana, E, Alvarez, Y, Durand, J, Slattery, J, Afonso, A, Requena, G, Huerta, C, Alvarez, A, de Abajo, F, Tauscher, M, Hasford, J, Fischer, R, Reynolds, R, and Schmiedl, S

Published
2015

16. Association of polymorphisms in the beta-2 adrenergic receptor gene with fracture risk and bone mineral density

Author

CDL Upod, Veldhuis-Vlug, A. G., Oei, L., Souverein, P. C., Tanck, M. W T, Rivadeneira, F., Zillikens, M. C., Kamphuisen, P. W., Maitland - van der Zee, A. H., de Groot, M. C H, Hofman, A., Uitterlinden, A. G., Fliers, E., de Boer, A., Bisschop, P. H., CDL Upod, Veldhuis-Vlug, A. G., Oei, L., Souverein, P. C., Tanck, M. W T, Rivadeneira, F., Zillikens, M. C., Kamphuisen, P. W., Maitland - van der Zee, A. H., de Groot, M. C H, Hofman, A., Uitterlinden, A. G., Fliers, E., de Boer, A., and Bisschop, P. H.

Published
2015

17. Incidence rates and trends of hip/femur fractures in five European countries:comparison using e-healthcare records databases

Author

Requena, G, Abbing-Karahagopian, V, Huerta, C, De Bruin, M L, Alvarez, Y, Miret, M, Hesse, U, Gardarsdottir, H, Souverein, P C, Slattery, J, Schneider, C, Rottenkolber, M, Schmiedl, S, Gil, M, De Groot, M C H, Bate, A, Ruigómez, A, García Rodríguez, L A, Johansson, S, de Vries, F, Montero, D, Schlienger, R, Reynolds, R, Klungel, O H, de Abajo, F J, Requena, G, Abbing-Karahagopian, V, Huerta, C, De Bruin, M L, Alvarez, Y, Miret, M, Hesse, U, Gardarsdottir, H, Souverein, P C, Slattery, J, Schneider, C, Rottenkolber, M, Schmiedl, S, Gil, M, De Groot, M C H, Bate, A, Ruigómez, A, García Rodríguez, L A, Johansson, S, de Vries, F, Montero, D, Schlienger, R, Reynolds, R, Klungel, O H, and de Abajo, F J

Abstract

Hip fractures represent a major public health challenge worldwide. Multinational studies using a common methodology are scarce. We aimed to estimate the incidence rates (IRs) and trends of hip/femur fractures over the period 2003-2009 in five European countries. The study was performed using seven electronic health-care records databases (DBs) from Denmark, The Netherlands, Germany, Spain, and the United Kingdom, based on the same protocol. Yearly IRs of hip/femur fractures were calculated for the general population and for those aged ≥50 years. Trends over time were evaluated using linear regression analysis for both crude and standardized IRs. Sex- and age-standardized IRs for the UK, Netherlands, and Spanish DBs varied from 9 to 11 per 10,000 person-years for the general population and from 22 to 26 for those ≥50 years old; the German DB showed slightly higher IRs (about 13 and 30, respectively), whereas the Danish DB yielded IRs twofold higher (19 and 52, respectively). IRs increased exponentially with age in both sexes. The ratio of females to males was ≥2 for patients aged ≥70-79 years in most DBs. Statistically significant trends over time were only shown for the UK DB (CPRD) (+0.7% per year, P < 0.01) and the Danish DB (-1.4% per year, P < 0.01). IRs of hip/femur fractures varied greatly across European countries. With the exception of Denmark, no decreasing trend was observed over the study period.

Published
2014

21. BackMatter.

Author

van Gestel, J. L. M., Hoeksema-Bakker, C. M. C., Keizer, H. A., and de Groot, M. C. H.

Published
1997

27. FrontMatter.

Author

van Gestel, J. L. M., Hoeksema-Bakker, C. M. C., Keizer, H. A., and de Groot, M. C. H.

Published
1997

30. Evaluation of patients’ experiences with antidepressants reported by means of a medicine reporting system.

Author

Geffen, E. C. G., van der Wal, S. W., van Hulten, R., de Groot, M. C. H., Egberts, A.C. G., and Heerdink, E. R.

Subjects
ANTIDEPRESSANTS, REPORTING of drug side effects, DRUG efficacy, INTERNET, MEDICAL care, MEDICAL personnel
Abstract

To assess experiences related to antidepressant use reported to an internet-based medicine reporting system and to compare the nature of the side effects reported by patients with those reported by health care professionals (HCPs). All reports submitted from May 2004 to May 2005 to an internet-based medicine reporting system in The Netherlands related to the use of antidepressants were analysed. Spontaneous reports of adverse drug reactions on antidepressants from HCPs received by The Netherlands Pharmacovigilance Centre Lareb from May 2004 to May 2005 were included for comparison. Of the 2232 individuals who submitted a report to the internet-based medicine reporting system, 258 submitted a report on antidepressants. Of these, 92 individuals (36%) reported on effectiveness, 40 (16%) of whom reported on ineffectiveness, and 217 (84%) submitted a report on side effects, with 202 (78%) reporting a total of 630 side effects that were experienced as negative. Fourteen individuals (5%) reported a practical issue and four (2%) reported a reimbursement issue. Of all 630 side effects reported, 48% resulted in the patient discontinuing the antidepressant therapy; of these 29% did not inform their HCP. Of all the side effects reported, 52% were perceived as “very negative”. In comparison to the side effects reported by HCPs, patients more often reported apathy, excessive sweating, ineffectiveness, somnolence, insomnia, sexual problems and weight increase. Patients report the ineffectiveness and side effects of antidepressant therapy as negative and leading to discontinuation of the therapy. Patients and HCPs differ in the nature of the reported side effects. Patient experiences should be included in the evaluation of antidepressant treatment in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

31. Seasonal changes in prescribing of long-acting beta-2-agonists-containing drugs.

Author

Rottenkolber M, Voogd E, van Dijk L, Primatesta P, Becker C, de Groot MC, Plana E, Alvarez Y, Durand J, Slattery J, Afonso A, Requena G, Huerta C, Alvarez A, de Abajo F, Tauscher M, Hasford J, Fischer R, Reynolds R, and Schmiedl S

Subjects
Administration, Inhalation, Adolescent, Adult, Asthma epidemiology, Child, Delayed-Action Preparations administration & dosage, Europe, Female, Humans, Male, Retrospective Studies, Seasons, Severity of Illness Index, Young Adult, Adrenergic beta-2 Receptor Agonists administration & dosage, Asthma drug therapy, Drug Prescriptions statistics & numerical data, Practice Patterns, Physicians'
Abstract

Background: For patients with asthma, COPD, or asthma-COPD overlap syndrome (ACOS), inter-country comparisons of seasonal changes in drug prescriptions are scarce or missing. Hence, we aimed to compare seasonal changes in prescription rates of long-acting beta-2-agonist (LABA) in four European countries., Methods: A common study protocol was applied to six health care databases (Germany, Spain, the Netherlands (2), and the UK (2)) to calculate age- and sex-standardized point prevalence rates (PPRs) of LABA-containing prescriptions by the 1st of March, June, September, and December of each year during the study period 2002-2009. Seasonal variation of PPRs was quantified using seasonal indexes (SIs; based on the ratio-to-moving-average-method) and SIs averaged over the study period (aSI) stratified by sex, age, and indication (asthma, COPD, or ACOS)., Results: There was a moderate seasonal change in LABA-containing prescriptions which was more pronounced in asthma or COPD patients compared to ACOS patients. For asthma and ACOS patients, highest seasonal variation was found for patients living in Spain (aSI: 87.3-110.7, aSI: 93.2-103.1) whereas for COPD highest seasonal variation was revealed for the NPCRD database (the Netherlands) (aSI: 92.2-105.6). Regarding age and sex, highest seasonal variation was found in Spanish boys under 10 years of age having a diagnosis of asthma., Conclusions: By applying a common analysis in six databases, we could observe moderate overall seasonal changes in LABA-containing prescription rates in patients with asthma, COPD, or ACOS., (Copyright © 2015 Elsevier Ltd. All rights reserved.)

Published
2015
Full Text
View/download PDF

33. [Severe adverse reactions after the use of sulphur hexafluoride (SonoVue) as an ultrasonographic contrast agent].

Author

de Groot MC, van Zwieten-Boot BJ, and van Grootheest AC

Subjects
Aged, Aged, 80 and over, Contrast Media administration & dosage, Fatal Outcome, Female, Humans, Male, Middle Aged, Respiratory Function Tests methods, Sulfur Hexafluoride administration & dosage, Contrast Media adverse effects, Sulfur Hexafluoride adverse effects
Abstract

European Medicines Agency (EMEA) recently took precautionary measures to limit the use of the ultrasonographic contrast agent sulphur hexafluoride (SonoVue) in patients with cardiac disease. Throughout Europe a number of serious allergic reactions with probable secondary cardiovascular problems have been reported. In addition to this, there have been 3 reports of a fatal outcome soon after the administration of SonoVue. For all of these patients there was a risk of serious cardiac complications as a consequence of underlying cardiac problems. In The Netherlands 3 anaphylactic reactions have been reported, two in women aged 59 and 70 years respectively, and one in a man aged 80 years.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results